Curcumin [1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, Fig. 1 ], a compound isolated from Curcuma longa L., has been used for centuries as dietary pigment and spice. Curcumin has been found to possess a variety of traditional pharmaceutical applications on diseases, including external/internal wounds, liver diseases (particularly jaundice), blood purification, microbial effects and inflamed joints.
Preclinical and clinic studies showed that, however, curcumin possesses several disadvantages in pharmacokinetics such as poor bioavailability, fast metabolism and requiring repetitive oral doses, 11, 12) which limited its applications. However, curcumin is still an excellent lead compound for drug design and development on the basis of the explicit bioactivities, non-toxicity and easy synthesis. [13] [14] [15] [16] Curcumin is stable at a pH below 6.5. The instability of curcumin at a pH above 6.5 is caused by the methylene group. 17) Omitting the methylene group and one carbonyl group, B. M. Markaverich, 18) M. Artico, 19) and H. I. El-Subbagh 20) synthesized series of mono-carbonyl curcumin analogues, 1,5-diaryl-1,4-pentadiene-3-ones, and evaluated their bioactivity. The result that the mono-carbonyl analogues exhibit more powerful inhibition in a variety of cancer cells than curcumin indicated that the central methylene group which had been considered the main active group of curcuminoids in antitumor property may be of decreasing importance.
Therefore, in the present paper three series of mono-carbonyl curcumin analogues without the central methylene functional groups, 1,5-diaryl-1,4-pentadiene-3-ones (B), together with cyclopentanone (A) and cyclohexanone (C) analogues ( Fig. 2) , were prepared and their anti-bacterial properties in vitro were evaluated and compared using seven multidrug-resistant bacteria specially causing secondary infections in human being. 21) These compounds were also designed to examine the role of different substitutes in the benzene ring and the influence of the space structure of the linking C-strain. It is hoped that continued research will lead to development of new lead compounds from curcumin as antibacterial agents and extrapolated agents for bacteria-infected diseases. Results and Discussion Chemistry The structure and general synthesis of analogues designed are shown in Fig. 2 and Chart 1. Most of three classes of compounds (A, B, C) were synthesized by coupling the appropriate aromatic aldehyde with cyclohexanone, acetone or cyclopentanone in an alkaline medium, respectively. 22) Reaction routes, yields, melting points and spectroscopic analysis such as NMR and mass spectroscopy are shown in Experiment Part. All reaction were carried out with a rate 2 : 1 of substituted arylaldehydes and ketones. The 1 H-NMR evidences that there did not appear the peaks of methyl adjacent to the carbonyl group in acetone analogues (or methylene peaks in cyclohexanone and cyclopentanone analogues) confirmed the absence of compounds substituted by single aryl ring.
Synthesis and Anti-bacterial Properties of Mono-carbonyl Analogues of Curcumin
For the synthesis of 13 and 14 analogues in alkaline condition, the use of 4-hydroxybenzaldehyde and 3-methoxy-4-hydroxybenzaldehyde required preventive protection of the hydroxyl groups, preferably with easily removable groups such as tetrahydropyran-2-yl.
19) The protected 4-(tetrahydropyran-2-yloxy)benzaldehyde, therefore, was obtained by reacting 4-hydroxybenzaldehyde with 3,4-dihydro-a-pyran in the presence of pyridinium p-toluenesulfonate (illustrated in Chart 2 as a representative example of the general procedure). To couple the protected derivatives with acetone, cyclopentanone and cyclohexanone, respectively gave compounds 07 and 11. Hydroxylated analogues 13 and 14 were then obtained by hydrolization with a catalytic amount of p-toluenesulfonic acid.
Compound 09 was prepared by coupling 5-bromofuran-2-aldehyde with three ketones respectively in alkaline medium, so did compound 15.
Biological Activity All compounds were evaluated and compared with curcumin for anti-bacterial activities against multidrug-resistant bacteria specially causing secondary infections in human being, Gram- 21, 23) Each test was performed in triplicate and the final results have been tabulated (Table 1) . It has been observed that part of the analogues exhibited interesting biological activity in different degree.
As can be seen in Table 1 , although not as active as the positive ampicillin, some compounds were generally found to be more active than the leading compound curcumin. Among the heterocycle substituted compounds, B09 and C09 showed good activities against all seven organisms, especially C09 against S. saprophyticus that appeared the largest zone of inhibition (21 mm) in our current experiments and was equal to ampicillin. B09 against S. aureus and S. saprophyticus as well as C09 against S. aureus and Micrococcus luteus also showed high activities. These indicated that the heterocycle (furan) substitution may enhance the bioactivities of curcumin analogues and moreover the acetone (B09) and cyclohexanone analogues (C09) are more active than cyclopentanone analogues (A09).
The compound A12, a novel compound with a long chain substituent of 3-(dimethylamino)propoxy, possessed excellent in vitro activity against all of 7 target pathogens. However, the dimethylamino substituted compounds (A04, B04, C04) showed weak activity, indicating the long and flexible chain out of the conjugation structure in A12 may play a important role in exhibiting bioactivity.
Among the six compounds with the phenolic groups (A13, A14, B13, B14, C13, C14), 1,4-pentadiene-3-one analogues B13 and B14 exhibited high activities against four Grampositive bacterial strains and moderate activity against three Gram-negatives. The cyclopentanone (A14) and cyclohexanone (C14) analogues showed moderate activity and A13 and C13, however, had low activities, which illustrated that the space structure of the linking C-strain can make some influence on the anti-bacterial ability.
Active compounds here were more effective against Grampositive organisms than against Gram-negatives. But the most encouraging result was that most of compounds exhibit activities against the Gram-negative E. cloacae that is completely resistant to the clinical drug ampicillin, which indicated that there may be a different mechanism of their antimicrobial action. So, it is possible to develop a novel agent against nosopoietic E. cloacae from mono-carbonyl curcumin analogues.
Although these compounds that possessed different substituents showed varying degrees of inhibition, among the three serial analogues designed, B compounds were more effective than the A and C compounds. Thus the nature and position of the substituent and the space of the linking strain have strong influence on the spectrum and extent of anti-bacterial activities.
Conclusion
Curcumin has been reported on the therapy of bacteriainfected diseases through inhibiting the bacterial endotoxininduced cytokines secretion and pathways activation, and directly suppressing pathogen cell growth. So, the anti-bacterial screening presented here may be also useful to find more advanced compounds for bacteria-induced inflammation and tumorigenesis. The bacteria used in this research were isolated from the clinical patients from First Affiliated Hospital of Wenzhou Medical College, and the inhibition to them also possessed more significant meanings in clinically medicinal therapy. In this paper, three series of mono-canbonyl analogues of curcumin, totaled to 40 compounds, have been synthesized and evaluated for anti-bacterial activities against seven multidrug resistant bacteria. It was observed that heterocycle or long-chain substituents may enhance the activity of curcumin analogues and the ampicillin-resisted Gram-negative E. cloacae was sensitive to most mono-canbonyl curcumin analogues.
Experimental
Chemistry Melting points were determined on a Fisher-Johns melting apparatus. 1 H-NMR spectra were recorded on a Varian INOVA-400 spectrometer. The chemical shifts are presented in terms of ppm with TMS as the internal reference. Electron-spray ionization mass spectra in positive mode (ESI-MS) were recorded on a Bruker Esquire 3000 ϩ spectrometer. Column chromatography purifications were carried out on Silica Gel 60 (E. Merck, 70-230 mesh). The purity of all new compounds was checked by thin-layer chromatography (TLC) and 1 H-NMR. All reactions were monitored by TLC on pre-coated Silica Gel F254 plates (purchased from Qingdao Marine Chemical Factory, China) with detection by UV. All reagents used were of analytical grade. 4-Fluorobenzaldehyde, 2-bromobenzaldehyde, 3,4-dihydroa-pyran, 2-fluoro-3-(trifluoromethyl)benzaldehyde, 5-bromofuran-2-aldehyde and 3-bromobenzaldehyde were purchased from Aldrich, U.S.A. Other reagents were purchased from Sinopharm Chemical Reagent Co., Ltd., China.
General Procedure of 01, 02, 03, 04, 06, 08, 09, 10 and 12 To a solution of 15 mmol arylaldehyde in MeOH (10 ml) was added 7.5 mmol ketone. The solution was stirred at room temperature for 20 min, followed by added 
12, 9, -10, -, -10, -, -9, -, -10, 9, --- 
15, 10, 8 14, 14, -21, 11, -13, 11, -11, 10, -10, -, -11, -, -
11, -, -13, 9, -10, 9, -13, 10, -10, -, - General Procedure of 07 and 11 A solution of 3,4-dihydro-a-pyran (22 mmol) in dichloromethane (20 ml) was added dropwise onto a wellstirred suspension of hydroxyl benzaldehyde (14.4 mmol) and pyridinium ptoluenesulfonate (0.16 mmol) in the same solvent (40 ml). The mixture was stirred at room temperature and monitored by TLC, then was washed with saturated NaHCO 3 solution (50 mlϫ3) and brine (50 mlϫ3) and dried over Na 2 SO 4 . Evaporation of the solvent gave crude product which was purified by column chromatography on silica gel (hexane/ethyl acetate, 7 : 3, as eluent) to obtain the mediate 4-(tetrahydropyran-2-yloxy) benzaldehyde as a lightly yellow oil (69-78% yield).
A mixture of protected derivative (6.94 mmol) and ketone (3.47 mmol) in C 2 H 5 OH (10 ml) was stirred at room temperature for 20 min; then 20% (w/v) NaOH (0.7 ml, 3.47 mmol) was added dropwise. After stirring for 60 min, the mixture was treated with 100 ml cold water and filtered. The residue was washed with ethanol and acetone and dried in vacuum. The product was purified by column chromatography on silica gel (hexane/ethyl acetate 9 : 1) to obtain 07 and 11.
(2E,5E)-2,5-Bis(4-(tetrahydro-2H-pyran-2-yloxy)benzylidene)cyclopen- General Procedure of 13 and 14 The protected product (07 or 11, 10 mmol) was suspended in methanol (40 ml) and treated with a catalytic amount of p-toluenesulfonic acid. After stirring at room temperature for 10 h the solvent was removed. The residue was treated with water and neutralized with a saturated solution of NaHCO 3 . The suspension was extracted with ethyl acetate (50 mlϫ3) and the collected organic extract was washed with brine (100 mlϫ3), followed by dried with Na 2 SO 4 . Evaporation of the solvent gave crude product and then recrystallization from C 2 H 5 OH/H 2 O to obtain pure 13 or 14.
(2E,5E)-2,5-Bis(4-hydroxybenzylidene)cyclopentanone (A13): Yellow crystal, 89.3% yield, mp Ͼ300°C. 
